Indeed, we have developed a single-chain variable fragment human Ab (scFv A7) that selectively targets pericytes in the RA synovium (92) and this Ab could be therapeutically exploited, in a bispecific format, to block PDGFR-β and inhibit pericyte-to-FDC differentiation. This evidence concerns the gene PDGFRB and rheumatoid arthritis.